Word: biotech
(lookup in dictionary)
(lookup stats)
Dates: during 2000-2009
Sort By: most recent first
(reverse)
...years here.” Tara A. Dunn ’01, was the only woman to be awarded a Life Science Fellowship this year. She spent some time after college working for a health care strategy consulting firm called Health Advances. The firm worked with pharmaceutical companies, biotech firms, and nonprofits, looking at how different health care firms could optimize treatment delivery opportunities. “I definitely knew that I wasn’t interested in being a lab scientist,” Dunn said, “I wanted to work at the intersection of business...
...firm. In core research areas, scientists are mining new sources for inspiration, be it China or genetic engineering. At the same time, Roche's bosses, from their base in Basel, continue to lead the pack in acquiring expertise, a talent recently seen in the company's bid to control biotech superstar Genentech. Together, the two strategies form the nucleus of how Roche plans to deliver best-in-class products--faster, more cheaply and more reliably--to market. "The days of an attrition-based pipeline are over," says Lee Babiss, head of global pharma research. "We've responded by making...
...obstacles still lie ahead for RNAi-based drugs, not least of which is how to best deliver them to patients. To solve that question, Roche turned to the outside. Last year Roche bought a 5% stake in Alnylam, a biotech start-up based in Cambridge, Mass., that's a leader in understanding RNAi...
...some estimates--but the deal will almost definitely go through. Nonetheless, Roche will have to work hard to hang on to Genentech's laid-back culture, one that has always attracted top minds. "They know there won't be the same flexibility and creativity Genentech is known for," says biotech analyst Geoff Porges of Sanford C. Bernstein & Co. "Roche is perhaps the industry's most brilliant acquirer, but it has never shown it can innovate internally...
...suffers as scientists guard their work to keep the money coming. Because the funding process favors experienced grant writers, young investigators can lose out. Such friction and lack of funds, some argue, are causing a brain drain to Singapore and other regions that are actively seeking to develop their biotech industries. "The incentives are totally misaligned. The repetitive nature of funding the same universities and the same people--all of these things add up to the stagnant position that we're in," says Doug Ulman, president of the LAF and chairman of the Director's Consumer Liaison Group...